Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Total Non-Current Liabilities (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Total Non-Current Liabilities for 11 consecutive years, with $422.5 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 3.53% to $422.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $422.5 million through Dec 2025, down 3.53% year-over-year, with the annual reading at $422.5 million for FY2025, 3.53% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $422.5 million at Cartesian Therapeutics, up from $407.7 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $451.0 million in Q3 2024, with the low at $32.6 million in Q3 2023.
  • Average Total Non-Current Liabilities over 5 years is $242.0 million, with a median of $148.4 million recorded in 2021.
  • The sharpest move saw Total Non-Current Liabilities tumbled 58.94% in 2022, then skyrocketed 1282.76% in 2024.
  • Over 5 years, Total Non-Current Liabilities stood at $111.9 million in 2021, then tumbled by 52.73% to $52.9 million in 2022, then soared by 740.32% to $444.7 million in 2023, then decreased by 1.5% to $438.0 million in 2024, then fell by 3.53% to $422.5 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $422.5 million, $407.7 million, and $391.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.